FUJIFILM reshapes life sciences leadership to accelerate cell therapy and iPSC expansion

Tomoyuki Hasegawa has been appointed CEO of FUJIFILM Biotechnologies California

Our vision is to make genomics as commonplace as BP monitor: Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences

We are building the bridge between complex molecular data and everyday clinical decisions

FICCI and Lilly launch Bharat Life Sciences Awards to recognise India’s scientific excellence

A first-of-its-kind national platform honouring the people and institutions shaping the next chapter of life sciences in India

Aragen Life Sciences elevates Pavan Kumar Kamarajugadda to Senior Director

Empowering life sciences and diagnostics with balanced, scalable technologies: Dev Ananthan, Director of Strategic Marketing, Danaher Lifesciences

Our Global Capability Center (GCC) in Bengaluru drives our major software development initiatives. Complementing this, our Bengaluru facility manufactures antibodies for research and diagnostics. Through these integrated technology and biotech operations, we are proud to contribute to India’s growth story in the life sciences sector.

Reliance Life Sciences appoints Siva Sankar Mahamkali as VP Biosimilars Manufacturing Operations

Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing

Dr. Abhigyan Upadhyay to lead Platinum Industries foray into life sciences

Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments

Alivus Life Sciences posts steady FY26 growth as margins surge past guidance

The company reported free cash flow of Rs. 2,590 Mn for FY26

Telangana life sciences ecosystem reaches $145 billion valuation

The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters

Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation

The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies